Results of both pilot and clinical studies recently showed that Phase 3 Sugar Controller, a patent-pending, proprietary combination of a specific form of L-arabinose and a patented form of chromium, significantly reduced both blood glucose and insulin responses to sucrose challenges, according to Pharmachem Laboratories, developer of the ingredient.

The pilot study of 20 healthy, non-diabetic subjects showed that taking Phase 3 Sugar Controller led to an average reduction in glucose of 31%, and an average reduction in insulin of 32% when presented with a 70 gram sucrose challenge. In the two-phase clinical trial of 50 healthy non-diabetic adults, subjects taking Phase 3 Sugar Controller had an average reduction in glucose of 24.3% and an average reduction in insulin of 28.2% when faced with the same sucrose challenge. The studies have been submitted for publication. For further information: www.pharmachemlabs.com